How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet.
Study Goal
The researchers aimed to evaluate the limitations of gluten-free diets for celiac disease and explore potential drug therapies targeting its pathophysiology.
Results Summary
The study highlights that strict gluten-free diets are challenging and often insufficient for many celiac disease patients, prompting drug development efforts. Several therapeutic approaches are in phase 2 and 3 clinical trials, targeting specific disease mechanisms.
Population
Patients with celiac disease, particularly those with nonresponsive or refractory forms (types I and II).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
strict, lifelong, gluten-free diet | decrease | celiac disease | patients | - | is the only proven treatment | #1 |
strict, lifelong, gluten-free diet | neutral | complete dietary gluten avoidance | patients | - | is challenging | #2 |
strict, lifelong, gluten-free diet | no change | disease activity | a substantial number of patients | - | do not respond fully, clinically, or histologically | #3 |
drug development | neutral | dietary treatment | patients with celiac disease | - | to address the limitations | #4 |
therapeutic approaches | neutral | celiac disease pathogenesis | - | - | target defined mechanisms | #5 |
therapeutic approaches | increase | phase 2 and 3 clinical studies | - | - | have advanced to | #6 |
The only proven treatment for celiac disease is adherence to a strict, lifelong, gluten-free diet. However, complete dietary gluten avoidance is challenging and a substantial number of patients do not respond fully, clinically, or histologically, despite their best efforts. As celiac disease is common and its central pathophysiology is well elucidated, it has become attractive for drug development to address the limitations of dietary treatment. Most efforts address nonresponsive celiac disease, defined as continued symptoms and/or signs of disease activity despite a gluten-free diet, and the more severe forms of refractory celiac disease, types I and II. An increasing spectrum of therapeutic approaches target defined mechanisms in celiac disease pathogenesis and some have advanced to current phase 2 and 3 clinical studies. We discuss these approaches in terms of potential efficiency, practicability, safety, and need, as defined by patients, regulatory authorities, health care providers, and payors.